Zevra Therapeutics closes sale of Rare Disease PRV for $150M

Zevra Therapeutics (ZVRA) announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $150M. Zevra was granted the PRV in September 2024 by the FDA, in connection with the FDA’s approval of MIPLYFFA, the first U.S. approved treatment for the ultra-rare neurodegenerative disease, Niemann-Pick type C. In addition, the Company reported that available unaudited cash, cash equivalents and investments as of Mar. 31, were $68.7M. Combined with the cash proceeds of $148.3M, net of fees, from the sale of the PRV after the end of the quarter, cash, cash equivalents and investments would be $217M.